

CLAIMS

1. Use of a NF- κ B inhibitor for the manufacture of a medicament for the treatment of
5 mastitis.
2. Use according to claim 1 wherein mastitis is chronic mastitis.
3. Use according to claim 1 wherein mastitis is acute mastitis.
10
4. Use according to any one of claims 1 to 3 in combination with antibiotics.
5. Use according to any one of the preceding claims wherein the NF- κ B inhibitor is a
15 specific NF- κ B inhibitor .
6. Use according to any one of the preceding claims wherein the NF- κ B inhibitor is
selected from 15d-PGJ2, tepoxalin, cycloepoxydon, (+)-cycloepoxydon, (-)-cyclo-
epoxydon , sodium diethyldithiocarbamate, gliotoxin, MG-132, BAY 11-7082,
20 BAY 11-7085 or bortezomib.
7. Use according to any one of the preceding claims wherein the NF- κ B inhibitor is
administered intramammary.